Compare · DXCM vs OSUR
DXCM vs OSUR
Side-by-side comparison of DexCom Inc. (DXCM) and OraSure Technologies Inc. (OSUR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and OSUR operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.08B, about 103.3x OSUR ($272.0M).
- Over the past year, DXCM is down 16.2% and OSUR is up 33.1% - OSUR leads by 49.3 points.
- DXCM has been more active in the news (30 items in the past 4 weeks vs 7 for OSUR).
- DXCM has more recent analyst coverage (25 ratings vs 5 for OSUR).
- Company
- DexCom Inc.
- OraSure Technologies Inc.
- Price
- $72.74-0.92%
- $3.94-1.25%
- Market cap
- $28.08B
- $272.0M
- 1M return
- +21.17%
- +34.01%
- 1Y return
- -16.20%
- +33.11%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 30
- 7
- Recent ratings
- 25
- 5
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
OraSure Technologies Inc.
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company operates in two segments, Diagnostics and Molecular Solutions. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company's principal products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND services, a suite of genomic services. In addition, the company offers ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, infectious disease diagnostics, pharmacogenomics, personalized medicine, microbime, and animal genetics markets. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.
Latest DXCM
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
- Director Driscoll Rimma was granted 5,605 shares, increasing direct ownership by 48% to 17,319 units (SEC Form 4)
- Director Ashley Euan A. was granted 5,565 shares, increasing direct ownership by 78% to 12,731 units (SEC Form 4)
- Director Collins Richard Alexander was granted 5,605 shares (SEC Form 4)
Latest OSUR
- OraSure Technologies Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Boyd Steven Kyle bought $224,750 worth of shares (75,000 units at $3.00), increasing direct ownership by 195% to 113,462 units (SEC Form 4)
- Director Bertrand John D. was granted 33,661 shares (SEC Form 4)
- SEC Form 3 filed by new insider Bertrand John D.
- Director Marmora Lelio covered exercise/tax liability with 28,406 shares, decreasing direct ownership by 22% to 102,354 units (SEC Form 4)
- Director Mcmahon Robert W. covered exercise/tax liability with 22,888 shares, decreasing direct ownership by 23% to 77,031 units (SEC Form 4)
- Director Gagliano Nancy J covered exercise/tax liability with 21,305 shares, decreasing direct ownership by 13% to 138,949 units (SEC Form 4)
- SEC Form 10-Q filed by OraSure Technologies Inc.
- OraSure Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- OraSure Announces First Quarter 2026 Financial Results